NEW YORK & LONDON & PARIS–(BUSINESS WIRE)–Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, is pleased to to announce that the United States Patent and Trademark Office (“US PTO”) has granted a patent for rapid liquid biopsy diagnostics technology of infectious disease pathogens (“RPIDD”) for the invention of a method of objective and simultaneous amplification in the preparation of DNA libraries (US patent no.: US11,280,028 B1) at the A*STAR institution, a Singapore-based entity with which Aptorum has signed an exclusive license agreement for the technology in question. A*Star has granted an exclusive license for the RPIDD technology to Aptorum, through its subsidiary Aptorum Innovations Holding Pte Limited.
The invention of RPIDD technology is based on a unique method of preparing DNA libraries from samples containing more than one type of nucleic acid, in very low quantity compared to non-nucleic acid molecules in the sample, with dramatically reduced time and significantly simplified steps compared to conventional DNA library preparation methods.
Mr. Darren Lui, President and Chief Executive Officer of Aptorum Group Limited said, “Through our collaboration partner A*STAR, we are delighted that the US PTO has recognized the uniqueness of our RPIDD technology and granted This patent.The patented RPIDD method will revolutionize traditional front-line clinical diagnostics for infectious diseases, such as blood culture, PCR, etc., and we believe that a rapid diagnostic approach based on molecular liquid biopsy for infectious diseases will disrupt current approaches, ultimately with the potential to reduce mortality and morbidity in infected patients. We are now focusing our efforts on clinical validation and market readiness of our patented RPIDD technology.”
About Atorum’s Rapid Pathogen Identification and Detection (RPIDD) Diagnostic Technology
RPIDD is an innovative rapid molecular diagnostic technology for the detection of pathogens by liquid biopsy. Proprietary technologies are in development to enrich pathogenic DNA/RNA for analysis leveraging the power of next-generation sequencing platforms and proprietary AI-based software analysis to identify and detect quickly any foreign pathogen (viruses, bacteria, fungi, parasites) through its genomic composition and to identify other unknown pathogens and new mutated pathogens. The RPIDD technology continues to be validated in human samples and, so far, this type of test has been able to detect pathogens (bacteria, fungi and viruses) with an objective approach. RPIDD is being validated in humans.
About Atorum Group Limited
Atorum Group Limited (Nasdaq: APM, Euronext Paris: APM) is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of therapeutic agents to treat diseases with unmet medical needs, particularly in the field of oncology (in particular orphan indications in oncology) and infectious diseases. Aptorum’s pipeline is also enriched through (i) the establishment of drug discovery platforms that enable the discovery of new therapeutic actives through, for example, systematic screening of existing approved drug molecules, and a microbiome-based research platform for the treatment of metabolic diseases; and (ii) the co-development, with Accelerate Technologies Pte Ltd, the commercialization arm of the Science, Technology and Research Agency of Singapore, of novel molecular technology for rapid pathogen identification and screening diagnostics .
For more information about Aptorum Group, please visit www.aptorumgroup.com.
Disclaimer and Forward-Looking Statements
This press release does not constitute an offer to sell or a solicitation of offers to buy securities of Atorum Group.
This press release contains statements about Atorum Group Limited and its future forecasts, plans and prospects that constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995. As such, all statements that contained in this release and which are not statements of historical fact may be deemed to be forward-looking statements. In some cases, forward-looking statements can be identified by the use of words such as “may”, “should”, “expect”, “plan”, “anticipate”, “could”, “intend”. , “intends”, “projects”, “considers”, “believes”, “estimates”, “predicts”, “potential”, or “continues”, or the negative form of these terms or other similar expressions. Aptorum Group has based these forward-looking statements, which include statements regarding expected timelines for application submissions and trials, primarily on its current expectations and projections regarding future events and trends that the group believes may affect its business. , financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions including, but not limited to, risks relating to the announced changes in the levels management and organization, the retention and availability of key personnel, the company’s ability to expand its product lines by offering additional products in other consumer segments, the results of its development activities, the company’s anticipated growth strategies, anticipated trends and challenges in its business, its expectations for and stability of its supply chain, the risks detailed on Form 20-F Aptorum Group and in other documents that the Company may file with the SEC in the future, as well as in the prospectus received by the Autorité des marchés financiers in France (visa n°20-352) on July 16 July 2020. Accordingly, the expectations contained in such forward-looking statements are subject to change and actual results could differ materially from those described in this press release.
The Atorum Group disclaims any obligation to update any forward-looking statements contained in this press release, whether in light of new information, future events or otherwise.
This publication does not constitute a prospectus within the meaning of Regulation (EU) n°2017/1129 of June 14, 2017, as amended by Delegated Regulations (EU) n°2019/980 of March 14, 2019 and n°2019/979 of March 14, 2019.
This press release is provided “as is” without any representations or warranties of any kind.
The text of the press release resulting from a translation should in no way be considered official. The only authentic version of the press release is that of the press release in its original language. The translation will always have to be compared with the source text, which will set a precedent.
Aptorum Group Limited
Investor Relations Department
+44 20 80929299
Redchip – financial communications, United States
+1 407 491 4498
Actifin – financial communications, Europe
+33 1 56 88 11 22